PubMed literature and ClinicalTrials.gov data across 35 exerkines
Number of PubMed-indexed publications per exerkine. Toggle between counts that co-mention “therapeutic” or “therapy” and total counts, over 5- or 10-year windows.
Total number of registered interventional studies on ClinicalTrials.gov for each exerkine, across all statuses and phases. Only exerkines with at least one trial are shown.
Percentage of each exerkine’s total publications that co-mention “therapeutic” or “therapy.” This keyword-based proxy approximates translational research emphasis: a higher ratio suggests more discussion of therapeutic potential relative to basic science.
Exerkines ranked by untapped therapeutic potential. Each bar shows the fraction of publications that co-mention “therapeutic” or “therapy” (green) versus those that do not (red). Molecules at the top have the largest research base with the lowest proportion of therapeutic keyword mentions — signaling where translational investigation may be lagging behind basic science interest.
Distribution of all exerkine-related clinical trials by phase. Shows the overall maturity of the translational pipeline — from early Phase 1 safety studies to post-market Phase 4 surveillance.
Per-exerkine breakdown of clinical trial phases. Wider late-phase segments (orange, pink) indicate molecules closer to regulatory approval.